Photosensitizers for photodynamic therapy of cutaneous disease

Journal of Dermatological Treatment

Volumn 14, Issue 2, 2003, Pages 107-112

  Stapleton, M ^a   Rhodes, Lesley E ^a,b  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cutaneous disorders; Photodynamic therapy; Photosensitizers; Singlet oxygen

Indexed keywords

5,10,15,20 TETRAKIS(4 SULFONATOPHENYL) 21H,23H PORPHINE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; CHLOROALUMINUM PHTHALOCYANINE; LEVULAN KERASTICKS; LUTETIUM TEXAPHYRIN; OXYGEN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PHTHALOCYANINE ZINC; PORPHIN; PROTOPORPHYRIN; PURYLTIN; REACTIVE OXYGEN METABOLITE; SINGLET OXYGEN; TALAPORFIN; TEMOPORFIN; TETRAHYDROXYPHENYLCHLORIN; TIN ETHYL ETIOPURPURIN; UNCLASSIFIED DRUG;

ARTICLE; DOSIMETRY; DRUG ACTIVATION; DRUG CLEARANCE; DRUG FORMULATION; DRUG PENETRATION; HUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; SKIN DISEASE;

EID: 0038022849     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630310012127     Document Type: Article

References (18)

1. Rhodes LE, Photodynamic therapy. Hosp Med (2000) 61: 160-1 (editorial).
2. Zane C, De Panfilis G, Calzavara-Pinton P, Photosensitizers - systemic sensitization. Photodynamic Therapy and Fluorescence Diagnosis in Dermatology (2001) 101-14.
3. Milgrom L, MacRobert S, Light ahead. Chem Br (1998) May: 45-50.
4. Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer. Drugs (1999) 5: 725-34.
5. Kreimer-Birnbaum M. Modified porphyrins, chlorins, phthalocyanines and purpurins: second generation photosensitisers for photodynamic therapy. Semin Haematol (1989) 26: 157-73.
6. Santoro O, Bandieramonte G, Melloni E et al, Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt administration in superficial basal cell carcinomas. Cancer Res (1990) 50: 4501-3.
7. Photodynamic therapy in dermatology. Arch Dermatol (1992) 128: 1631-6(editorial).
8. Kalka K, Merk H, Mukhtar H, Photodynamic therapy in dermatology. J Am Acad Dermatol (2000) 42: 389-413.
9. Renschler MF, Yuen A, Panella TJ et al, Photodynamic therapy trials with lutetium texaphyrin PCI-0123 (Lu-Tex). Photochem Photobiol (1997) 65 (suppl): 47S-8.
10. Knubler AC, Hasse T, Staff C et al, Photodynamic therapy of primary nonmelanomatous skin tumors of the head and neck. Laser Surg Med (1999) 25: 60-8.
11. Young C, Mukhtar H, Tubesing K et al, Pc4 PDT cutaneous photosensitivity and tumor regression occur through disparate mechanisms. Photochem Photobiol (1994) 59 (suppl): 32-5.
12. Kennedy JC, Pottier RH, Photodynamic therapy with endogenous protoporphyrin IX: basic principles and current clinical experience. J Photochem Photobiol B (1990) 6: 143-8.
13. Rhodes LE, Tsoukas MM, Anderson R, Kollias N, Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermatol (1997) 108: 87-91.
14. Morton C, Wong GAE, Taylor D et al, Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol (2002) 146: 552-67.
15. Orenstein A, Kostenich G, Roitman L et al, Photodynamic therapy of malignant lesions of the skin mediated by topical application of 5-aminolevulinic acid in combination with DMSO and EDTA. Lasers In the Life Sciences (1996) 7: 49-57.
16. Tope WD, Ross EV, Kollias N et al, Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochem Photobiol (1998) 67: 249-55.
17. Fijan S, Hönigsmann H, Ortel B, Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol (1995) 133: 282-8.
18. Barry B, Dermatological formulations: percutaneous absorption. Marcel Dekker: New York. 1983.